A whole-food diet reduced a marker of intestinal inflammation by 37% compared with a usual diet among healthy first-degree relatives of patients with Crohn’s disease (CD) who were at increased risk of developing the condition, according to a small, randomized trial published in Gastroenterology. The authors wrote that larger, longer-term trials are needed to determine whether the changes lower the risk of CD.
The results come from the PIONIR trial, which evaluated the Tasty&Healthy diet in relatives with persistently elevated fecal calprotectin (FC) levels, a marker of intestinal inflammation.
“This proof-of-concept study demonstrates that a dietary intervention can modify biomarker-defined intestinal inflammation in selected high-risk first-degree relatives without overt CD,” wrote the researchers, who were led by first author Dan Turner, MD, PhD, of Shaare Zedek Medical Center and the Hebrew University of Jerusalem, Israel. “To our knowledge, this is the first published randomized controlled trial evaluating an intervention in at-risk individuals with persistent low-grade intestinal inflammation but without diagnostic endoscopic evidence of IBD.”
To determine whether dietary changes could reduce inflammation during a possible early stage of CD, the researchers screened 331 first-degree relatives of patients with the condition and identified 33 who qualified for the trial. Of these, 29 were randomly assigned to begin either the Tasty&Healthy diet or their usual diet.
Participants were 6 to 38 years old and had FC levels above 70 µg/g on repeated tests. Capsule endoscopy or ileocolonoscopy showed either normal findings or minor abnormalities, such as swelling of the intestinal lining or up to 10 small ulcers.
The trial used a crossover design. Fourteen participants followed the Tasty&Healthy diet for eight weeks, while 15 continued their usual diets. The groups then switched diets for another eight weeks, allowing researchers to compare the effects of both diets in the same participants. The primary outcome was reduction in FC levels across both periods.
The intervention diet excluded processed foods, gluten, red meat, and most dairy products, although plain yogurt was allowed. Participants did not have to eat specific foods, use nutritional formulas, or limit calories. During both diets, they received weekly guidance from a dietitian and food vouchers.
Fecal calprotectin results
After the first eight weeks, median FC levels were 64 µg/g among participants following the Tasty&Healthy diet vs. 112 µg/g among those continuing their usual diets.
FC levels fell by at least 50% in 71% of participants following the Tasty&Healthy diet vs. 27% of those continuing their usual diets. Half of those following the Tasty&Healthy diet achieved normal FC levels, compared with 27% of those on their usual diets, although the difference was not statistically significant.
Across both treatment periods, adjusted FC levels fell by 61%, from 185 to 72 µg/g, during the Tasty&Healthy diet, compared with a 38% reduction, to 114 µg/g, during periods when participants followed their usual diets.
FC levels rose when participants returned to their usual diets and fell when those initially assigned to their usual diets switched to Tasty&Healthy.
The diet had similar effects among 21 participants with minor abnormalities found during endoscopy and eight with normal findings.
Each additional gram of fiber consumed daily during the intervention was associated with a 3.5% decrease in FC levels.
Participants with higher C-reactive protein levels at the start of the trial had smaller reductions in FC levels. Age, sex, and having multiple relatives with CD were not associated with the response to the diet.
Other findings
The diet also changed the types of bacteria in the gut. Two bacterial species increased during the Tasty&Healthy diet, while four decreased. Among those that declined was Ruminococcus torques, a bacterium previously linked to the breakdown of intestinal mucus and inflammatory bowel disease.
White blood cell counts were 11% lower during the Tasty&Healthy diet than during periods when participants followed their usual diets. Platelet counts and C-reactive protein levels also fell, but those differences were not statistically significant.
Participants consumed more fiber, potassium, and vitamin E and less saturated fat and ultra-processed food. Median daily fiber intake was 26.5 grams during the intervention vs. 17.7 grams when participants followed their usual diets.
Most participants followed the diet closely, with 83% showing good or complete adherence. After eight weeks, 79% found the diet acceptable. Food-related quality of life was similar between the two diets.
Three participants reported mild adverse events: two had abdominal pain during the Tasty&Healthy diet, and one had hemorrhoids and abdominal pain after resuming their usual diet. All resolved after dietary adjustments, and no cases of avoidant/restrictive food intake disorder were observed.
Implications and limitations
The researchers noted that the findings demonstrate short-term changes in inflammatory markers rather than long-term clinical benefits.
Study limitations included the small number of participants, short treatment periods, no break between diets, and an open-label design, although clinicians and laboratory staff were blinded to diet assignment. Persistent FC elevation has been associated with future CD risk, but the authors noted that FC is a nonspecific marker and cannot establish that all participants were progressing toward the disease.
The authors said numerically lower calcium intake during the diet, although not statistically significant, should be considered in the minority of patients whose FC rises when dairy is reintroduced. They also cautioned that restrictive diets may promote food-related anxiety, avoidance, or nutritional inadequacy, which they said underscores the need for dietitian supervision.
The researchers plan to follow participants annually and conduct additional analyses of markers of inflammation.
“Whether sustained biomarker modification translates into a lower risk of progression to CD remains to be determined in larger, longer-term trials,” the authors wrote.
The Leona M. and Harry B. Helmsley Charitable Trust funded the trial. Dr. Turner reported no conflicts relevant to the manuscript but disclosed ties to companies including Janssen, Pfizer, AbbVie, Takeda, and Lilly. Nine coauthors reported ties to companies including AbbVie, Janssen, Takeda, Lilly, and Nestlé Health Science; the others reported none.